Eli Lilly Tirzepatide's Phase III trial in obese or overweight adult patients in China was successful

On February 2, Eli Lilly announced that its glucose-dependent insulin stimulating peptide (GIP) and glucagon-like peptide-6 (GLP-1) receptor agonist Tirzepatide, a phase III trial SURMOUNT-CN in obese or overweight adults in China, met the primary endpoint and all key secondary endpoints. In this trial, the overall safety profile of Tirzepatide was similar to that reported in previous trials, with no new safety signals identified.

Following the 2022 New England Journal of Medicine reporting the blockbuster results of Tirzepatide's world's first obese or overweight phase III trial, SURMOUNT-1, the SURMOUNT-CN trial once again validated the positive results in Chinese population. The trial data is being further collated and analysed, and the results will be published in peer-reviewed academic journals.

About Tirzepatide

The innovative drug Tirzepatide is the world's first approved weekly GIP/GLP-1 receptor agonist. Tirzepatide was approved by the U.S. Food and Drug Administration (FDA) in May 2022 to improve glycemic control (on a dietary basis and exercise) in adults with type 5 diabetes and is currently approved in the European Union, Japan and other countries.